Privium Fund Management B.V. Acquires 22,500 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Privium Fund Management B.V. lifted its holdings in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 22.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,000 shares of the company’s stock after buying an additional 22,500 shares during the period. Privium Fund Management B.V. owned approximately 0.26% of 4D Molecular Therapeutics worth $674,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its holdings in shares of 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after acquiring an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after purchasing an additional 9,737 shares during the last quarter. AlphaQuest LLC boosted its holdings in 4D Molecular Therapeutics by 3,665.2% in the fourth quarter. AlphaQuest LLC now owns 14,835 shares of the company’s stock worth $83,000 after purchasing an additional 14,441 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $166,000. Finally, Proficio Capital Partners LLC raised its stake in 4D Molecular Therapeutics by 100.0% during the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $111,000 after buying an additional 10,000 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Price Performance

FDMT opened at $3.82 on Wednesday. The company has a 50 day simple moving average of $4.81 and a two-hundred day simple moving average of $7.62. The firm has a market cap of $176.87 million, a P/E ratio of -1.34 and a beta of 2.83. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.73 and a 1-year high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on FDMT. Leerink Partners cut their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price target for the company from $40.00 to $15.00 in a research note on Monday, January 13th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Chardan Capital cut their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada reduced their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.63.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.